NanoSmart Pharmaceuticals and University of California Los Angeles (UCLA) have signed a research alliance to advance the development of the drug delivery platform that uses human autoimmune antibodies targeting several tumor types.
NanoSmart Pharmaceuticals president Dr. James Smith said the collaboration will facilitate access to UCLA's high level of research, development and clinical resources.
"Their expertise in the development of nanotechnology-based drugs will enable us to continue making efficient progress towards commercializing these products," Smith added.
The integration of the NanoSmart's patented technology with the cancer drugs, which previously received FDA approval, is expected to result in range next-generation cancer drug candidates that could be safer and much more effective.
